June 18, 2008 - HemoCue(R) AB, a global point-of-care diagnostic test manufacturer and wholly owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), announced that its HemoCue Albumin 201 System is the first quantitative point-of-care test for screening for, diagnosing and monitoring microalbuminuria to be granted a CLIA waiver by the U.S. Food and Drug Administration (FDA). With the FDA CLIA waiver, non-laboratory trained physicians and other health care professionals in any health care facility with a CLIA Certificate of Waiver in the U.S. will be able to use the HemoCue Albumin 201 System to screen patients for microalbuminuria and begin treatment based on the test's results during a single office visit.
Microalbuminuria may indicate the presence of chronic kidney disease (CKD), a life-threatening condition that affects approximately 26 million Americans. Diabetes and hypertension are the two leading risk factors for developing CKD. Microalbuminuria also is an independent risk factor for developing cardiovascular disease in patients with or without diabetes or hypertension... Quest Diagnostics' Press Release -
Blog Archive
-
▼
2008
(233)
-
▼
July
(23)
- MicroIslet : Safety and Efficacy Data Update
- CombinatoRx : Progress in Key Programs at 2008 R&D...
- Metabolon : Collaboration with the University of T...
- Santarus and Depomed : U.S. Promotion Agreement fo...
- International Stem Cell and Novocell : Collaborati...
- XOMA 052 Phase 1 Data to be Presented At European ...
- Hollis Eden Pharmaceuticals : Phase II Clinical Tr...
- Genaera : Data on Mechanism of Inhibition of PTP-1...
- Emisphere Technologies : Data From Independent Cli...
- Animas Corporation : OneTouch Ping Glucose Manage...
- Echo Therapeutics : Clinical Study of Its Symphony...
- BodyTel : to Launch GlucoTel System in August
- Axis-Shield : AFINION HbA1c patent granted in USA
- AgaMatrix : New WaveSense Presto and Pro Glucose M...
- ARKRAY USA : National Launch of GLUCOCARD X-METER
- Georgetown University Teams with Gentag and SAIC :...
- Emisphere : License Agreement With Novo Nordisk to...
- Debiotech and STMicroelectronics : First Prototype...
- Abbott : Phase III Sub-Group Analysis Shows Invest...
- ProStrakan : Novel Testosterone Gel Significantly ...
- Isis : Robust Drug Portfolio for Diabetes and Obes...
- Sangamo BioSciences : Presentation of Phase 1b ZFP...
- HemoCue : First FDA CLIA Waiver in Diagnostics Ind...
-
▼
July
(23)